Navigation Links
Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Date:9/15/2008

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has revised the expected timing of its announcement of results for the CLIRS trial, the company's Phase III clinical trial of Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections.

Cadence is currently engaged in discussions with the U.S. Food and Drug Administration (FDA) regarding the statistical analysis plan for the CLIRS trial. These discussions, which are being conducted under a Special Protocol Assessment (SPA), must be completed prior to unblinding the data from the trial. As a result, Cadence has revised the expected timing of its announcement of results for the CLIRS trial from the fourth quarter of 2008 to the first quarter of 2009. If the trial is successful, Cadence continues to plan for submission of a New Drug Application (NDA) for Omigard in the second quarter of 2009.

About the CLIRS trial

The CLIRS trial, or Central Line Infection Reduction Study, is Cadence's confirmatory Phase III clinical trial of Omigard(TM) for the prevention of catheter-related infections. The CLIRS trial is a multi-center, randomized, evaluation committee-blinded study in patients whose medical condition requires a central venous catheter. The primary efficacy endpoint of the clinical trial is to evaluate whether Omigard is superior to 10% povidone-iodine in the prevention of local catheter-site infections. The CLIRS trial, which has completed enrollment of over 1,850 patients randomized to receive either Omigard or 10% povidone-iodine, is designed to have 80% power to detect significance at the 0.05 level. The CLIRS trial is being conducted under an SPA with th
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
4. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
5. Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
8. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
9. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
10. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
11. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Strategy for ... ... SGMO ) announced today the publication of data,demonstrating that human immune ... treatment with zinc finger DNA-binding,protein nucleases (ZFN(TM)). The data suggest that ...
... mention ongoing FDA-approved HIFU clinical trials in the, ... and experience, CHARLOTTE, N.C., June 27 USHIFU, ... for prostate cancer,treatment in North and South America, announced ... featured a segment on high intensity focused,ultrasound (HIFU) for ...
Cached Medicine Technology:Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 2Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 3Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 4Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 5Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 6ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 2ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 3
(Date:4/18/2014)... -- A group of scientists from the University ... Center on Aging has found interesting new information ... in Parkinson,s disease (PD). , Published in ... which assessed cognitive function in depressed and non-depressed ... therapy commonly used to treat motor symptoms of ...
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... year’s polio outbreak on the wane and excellent coverage ... Group today advised// the government that the next few ... most vulnerable children, who are not being sufficiently immunized ... and international experts who advised the government on strategies ...
... Delhi: Reliance Life Sciences, the biotechnology venture of Mukesh Ambani's ... and building// a world class manufacturing unit to produce them. ... unit due to the response to its Factor VII product, ... of Factor VII in their blood that leads to serious ...
... which happens as people catch up with age is fine, but ... have major repercussions on health, increasing the chances of early death. ... 3 centimeters or more in height of men as they age ... men who lose less than a centimeter. This risk was thought ...
... study involving more than 413,000 persons from 10 countries has ... activity or two hours// of moderate activity can cut the ... 35 per cent. ,Christine Friedenreich of the International Agency ... Cancer Board carried out the study to assess how ...
... from University of Sydney suggested that having an epidural ... breastfeeding//. The study results were published in the December ... who studied 1,300 women who gave birth between March ... anaesthetic are more likely to have problems in the ...
... India, has come up with another project. This scheme named ... to cost Rs 342.81-crores. ,The Global Fund aids ... will also be spent for reducing the transmission of HIV ... including antiretroviral therapy to those already infected. ,There ...
Cached Medicine News:Health News:Polio Outbreak on Wane: Next Rounds Must Focus on Youngest Children 2
Skin Tone External Eyelid Weights...
To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
Zone Quick is a simple and accurate system that measures tear volume in just 15 seconds per eye. Each box has an easy to read diagnostic indicator rule....
... Stent has been introduced by FCI Ophthalmics, Inc. ... Lacrimal Stent addressed the limitations previously encountered with ... DCR. Brought in to position through the nose, ... is no need to pass the very large ...
Medicine Products: